Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 81.01% is 13% above its 5-year average of 71.94%, around the middle of its 5-year range (48.65%–109.79%).
As of the fiscal period ended Wednesday, December 31, 2025. 6.31% above its 12-month average of 76.20%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
81.01%
RETURN ON EQUITY (ROE) AVG TTM
76.20%
RETURN ON EQUITY (ROE) AVG 3Y
64.92%
RETURN ON EQUITY (ROE) AVG 5Y
71.94%
RETURN ON EQUITY (ROE) AVG 10Y
74.36%
RETURN ON EQUITY (ROE) AVG 15Y
42.77%
RETURN ON EQUITY (ROE) AVG 20Y
36.04%
CURRENT VS TTM AVG
+6.31%
CURRENT VS 3Y AVG
+24.78%
CURRENT VS 5Y AVG
+12.61%
CURRENT VS 10Y AVG
+8.95%
CURRENT VS 15Y AVG
+89.40%
CURRENT VS 20Y AVG
+124.80%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+643.89%
vs the sector median at left
Eli Lilly and Company
Market Cap
$1.08T
Return on Equity (ROE)
81.01%
TTM Avg
76.20%
3Y Avg
64.92%
5Y Avg
71.94%
Market Cap
$617.78B
Return on Equity (ROE)
24.76%
TTM Avg
26.27%
3Y Avg
31.76%
5Y Avg
29.75%
Market Cap
$443.24B
Return on Equity (ROE)
-129.24%
TTM Avg
-0.29%
3Y Avg
28.74%
5Y Avg
37.53%
Market Cap
$376.34B
Return on Equity (ROE)
13.51%
TTM Avg
14.18%
3Y Avg
19.86%
5Y Avg
21.18%
Market Cap
$321.62B
Return on Equity (ROE)
19.48%
TTM Avg
35.83%
3Y Avg
26.05%
5Y Avg
27.71%
Market Cap
$213.42B
Return on Equity (ROE)
13.24%
TTM Avg
12.70%
3Y Avg
13.51%
5Y Avg
15.24%
Market Cap
$209.19B
Return on Equity (ROE)
60.74%
TTM Avg
61.58%
3Y Avg
67.05%
5Y Avg
123.42%
Market Cap
$207.87B
Return on Equity (ROE)
84.87%
TTM Avg
79.33%
3Y Avg
111.35%
5Y Avg
101.76%
Market Cap
$184.11B
Return on Equity (ROE)
10.61%
TTM Avg
20.32%
3Y Avg
18.59%
5Y Avg
17.97%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eli Lilly and Company (LLY) | $1.08T | 81.01% | 76.20% | 64.92% | 71.94% |
| Johnson & Johnson (JNJ)vs › | $617.78B | 24.76% | 26.27% | 31.76% | 29.75% |
| AbbVie Inc. (ABBV)vs › | $443.24B | -129.24% | -0.29% | 28.74% | 37.53% |
| UnitedHealth Group Incorporated (UNH)vs › | $376.34B | 13.51% | 14.18% | 19.86% | 21.18% |
| Merck & Co., Inc. (MRK)vs › | $321.62B | 19.48% | 35.83% | 26.05% | 27.71% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $213.42B | 13.24% | 12.70% | 13.51% | 15.24% |
| Novo Nordisk A/S (NVO)vs › | $209.19B | 60.74% | 61.58% | 67.05% | 123.42% |
| Amgen Inc. (AMGN)vs › | $207.87B | 84.87% | 79.33% | 111.35% | 101.76% |
| Abbott Laboratories (ABT)vs › | $184.11B | 10.61% | 20.32% | 18.59% | 17.97% |
| Gilead Sciences, Inc. (GILD)vs › | $161.66B | 39.19% | 19.98% | 21.60% | 19.44% |
ROE
81.0%
ROA
21.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 77.78% |
| 2024-12-31 | 74.62% |
| 2023-12-31 | 48.65% |
| 2022-12-31 | 58.64% |
| 2021-12-31 | 62.16% |
| 2020-12-31 | 109.79% |
| 2019-12-31 | 319.09% |
| 2018-12-31 | 32.88% |
| 2017-12-31 | -1.76% |
| 2016-12-31 | 19.54% |
| 2015-12-31 | 16.53% |
| 2014-12-31 | 15.55% |
| 2013-12-31 | 26.57% |
| 2012-12-31 | 27.69% |
| 2011-12-31 | 32.11% |
| 2010-12-31 | 40.82% |
| 2009-12-31 | 45.45% |
| 2008-12-31 | -30.76% |
| 2007-12-31 | 21.87% |
| 2006-12-31 | 24.25% |
| 2005-12-31 | 18.34% |
| 2004-12-31 | 16.58% |
| 2003-12-31 | 26.22% |
| 2002-12-31 | 32.73% |
| 2001-12-31 | 39.13% |
| 2000-12-31 | 50.57% |
| 1999-12-31 | 54.28% |
| 1998-12-31 | 47.36% |
| 1997-12-31 | -8.29% |
| 1996-12-31 | 24.98% |
